The FDA is aware of four recent studies that examined a possible leak between Lantus and cancer. Lantus is an insulin product used to treat diabetes. Three of the four recently published studies suggest that diabetes patients who use Lantus have an increased risk of developing cancer. The FDA is now reviewing safety information for Lantus, including the four recently released studies and Lantus clinical trials. With this review, the FDA seeks to determine whether Lantus use does pose an increased of cancer. Also, the FDA is having discussions with the Lantus manufacturer to decide whether more studies are needed to evaluate the drug’s safety and efficacy.
According to the FDA, patients should not stop taking their insulin treatment without first talking with their doctor, due to the adverse effects of uncontrolled blood sugar.